Kyowa Kirin Unveils Strong Burosumab Benefits for XLH Patients
Kyowa Kirin Examines Burosumab's Efficacy in Real-world Studies
Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), has recently presented compelling new research indicating statistically significant improvements in patient-reported outcomes (PROs) for adults dealing with X-linked hypophosphatemia (XLH). This presentation highlights the meaningful impact of burosumab (CRYSVITA) treatment, shared with attendees at a major annual meeting on bone and mineral research.
Understanding X-linked Hypophosphatemia
XLH is a rare genetic condition that poses challenges for individuals, leading to various skeletal issues and discomfort. This retrospective study focused on the experiences of 136 individuals who were new to burosumab treatment and enrolled in a specific early access program. The improvements observed over periods of six and 12 months of treatment emphasized the importance of burosumab in managing XLH effectively.
Results of the Study: Key Findings
Significantly, improvements were noted in various metrics measuring patient experience. The following domains expressed notable positive change:
Evaluating Patient-Reported Outcomes
- Brief Pain Inventory-Short Form (BPI-SF) scores for Worst Pain, Pain Severity, and Pain Interference showed improvement.
- Western Ontario and McMaster Universities Arthritis Index (WOMAC) demonstrated enhancements in Stiffness, Physical Function, Pain, and Total Scores.
- EuroQol 5-Dimension (EQ-5D) assessments revealed better utility and visual analogue scale scores.
These results strengthen the understanding of how burosumab contributes to alleviating symptoms related to XLH, as well as improving overall health-related quality of life.
Expert Insight into the Findings
Dr. Judith Bubbear, a lead investigator in the study, remarked on the significance of these outcomes, emphasizing their implications for patient care. Alongside improved health metrics, she noted that the study also traced sustained enhancements in serum phosphate levels, a critical factor for individuals suffering from XLH.
Commitment to Advancing Treatment for XLH
Kyowa Kirin stands firm in its commitment to improve understanding and treatment options for XLH, highlighting the necessity of collaboration with healthcare professionals and the community. Ben Johnson, a global HEOR lead at Kyowa Kirin, expressed his team’s dedication to pushing the boundaries of research to provide the best possible outcomes for patients.
About Burosumab and Its Role
Burosumab is a breakthrough treatment option, a recombinant human monoclonal antibody designed to impede the action of FGF23, a protein crucial in regulating phosphate levels within the body. By restoring the balance of phosphate, burosumab gives hope to many living with XLH.
Kyowa Kirin's Vision for the Future
As a leader in the pharmaceutical space, Kyowa Kirin dedicates itself to developing transformative therapies that significantly enhance the quality of life for patients affected by severe and rare conditions. With over 70 years of experience in drug development, the company is well-positioned to explore innovative medicines that prioritize patient care and support multidisciplinary treatment approaches.
Frequently Asked Questions
What is X-linked hypophosphatemia?
X-linked hypophosphatemia (XLH) is a genetic bone disorder that leads to low phosphate levels, causing various skeletal abnormalities and pain.
How does burosumab treat XLH?
Burosumab (CRYSVITA) works by inhibiting the action of FGF23, helping to restore normal phosphate levels in the body.
What were the highlights of the recent study?
The study demonstrated statistically significant improvements in pain, physical function, and overall quality of life for patients undergoing burosumab treatment.
Who conducted the research on burosumab?
The research was carried out by Kyowa Kirin in collaboration with healthcare professionals focusing on the impact of XLH on patients’ daily lives.
What is Kyowa Kirin's mission?
Kyowa Kirin aims to discover and develop medicines that bring transformative effects, especially for patients dealing with severe and rare diseases.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- GXO Logistics Collaborates with Forum Sport to Enhance Supply Chain
- Innovative Authentication Solutions for Secure Industries Unveiled
- Vitalik Buterin Advocates for Crypto Prediction Market Polymarket
- Innovative Partnership Boosts SWIR Imaging Solutions for All
- Relu Achieves FDA Clearance and CE Mark for Dental Innovation
- Glenn Fishwick Takes Charge as CTO at CSL Group for Connectivity Innovation
- Appy Pie Unveils 'Endpoint' API Platform for AI Integration
- Goldman Sachs Optimizes Gold Projections for 2025 Prices
- Atlassian Stock Receives Upgraded Forecast for Future Growth
- Meta Platforms Inc. Positioned for Growth Amid Market Challenges
Recent Articles
- Shigeru Ishiba's Leadership: Impacts on Japan-U.S. Relations
- Hafnia Limited Transitions Smoothly to Singapore Corporate Structure
- Transforming Hotel Marketing: The Cloudbeds and Mirai Alliance
- BearingPoint Achieves B Corp Certification for Sustainability
- Wolters Kluwer Elevates Richard Pulliam to Senior Executive Role
- Volt Lithium's Role in Upcoming Investor Gatherings
- Mark Cuban’s Evolving Views on Trump: A Complicated Relationship
- Tesla Drivers Can Soon Enjoy the Smart Summon Feature
- Leadership Transition at Concentric AB: What to Expect
- Cupshe Launches New Collection for Breast Cancer Awareness Month
- Neuraxpharm extends its CNS product reach in the Middle East
- Thoma Bravo's Strategic Investment in USU: A Bright Future
- Exploring Power Nickel's Promising Lion Zone Assay Results
- TaylorMade Golf Elevates Labeling Efficiency with TEKLYNX Solutions
- Innovative Use of Silicones in Automotive and Healthcare Solutions
- CME Group Introduces Innovative Micro Nikkei Futures Trading
- Joe Jonas and PlanetPlay Unite for Environmental Action
- Public Focus on Strengthening U.S. Retirement System Priorities
- Volvo Group's Joachim Rosenberg Steps Down After Two Decades
- Implantica Hosts User Meeting for Surgeons Advancing Reflux Care
- Sri Lanka Engages IMF for Crucial $2.9 Billion Bailout Talks
- The ECB's Evolving Monetary Policy: Implications and Outlook
- Spar Nord Bank's Share Buybacks: Insights from Recent Transactions
- Acuity Brands and Nike: Key Stocks to Monitor Today
- Loomis AB Completes Share Repurchase Program Successfully
- Market Analysis: Australia Stocks Close Lower Amid Sector Losses
- Positive Momentum in the Japanese Stock Market and Key Players
- Analyzing the Impact of USD/CAD on S&P 500 Trends
- Warren Buffett's Strategic Bet on Occidental Petroleum Shares
- Small Caps Eye Breakout as S&P 500 Provides Momentum
- OMass Therapeutics Strengthens Team and Advances MC2 Candidate
- Interposer and Fan-Out WLP Market Insights: Growth Trends
- BlackRock Inc. Reports Significant Shareholding Changes in Syensqo
- Nextracker Launches Innovative Solar R&D Center in India
- Veolia's Innovative District Heating Project Enhances UK Decarbonization
- Nidec Expands Horizons with Acquisition of Linear Transfer Automation
- Join ASSA ABLOY's Exciting Q3 Report Presentation Event!
- Leadership Transition at Concentric AB: Key Changes Ahead
- BancTrust Unveils New Head for Global Debt Capital Markets
- BitKan Expands Trading Options with Binance COIN-M Futures
- Aker BP ASA's Cash Offer for Senior Notes: Key Details Explained
- Sivers Semiconductors Secures Funding to Advance Chip Technology
- Hurricane Helene Leaves Millions Without Power in the U.S.
- Pfizer Reduces Stake in Haleon for $3.3 Billion: Key Details
- Fed's Michelle Bowman Advocates for Cautious Rate Adjustments
- Understanding the Hidden Struggles of Today's Economy
- Priority Review for ENHERTU® in HER2 Low Metastatic Cancer
- Concentric AB Strengthens Portfolio with GO Engineering Purchase
- Assan Alüminyum's Vision for a Sustainable Future by 2050
- GIGABYTE Launches Revolutionary X870E/X870 Motherboards